Evidence map›Paper›PMID 38324585›Full record

ArticlePLoS computational biology2024

Trafficking dynamics of VEGFR1, VEGFR2, and NRP1 in human endothelial cells.

Sarvenaz Sarabipour, Karina Kinghorn, Kaitlyn M Quigley, Anita Kovacs-Kasa, Brian H Annex, Victoria L Bautch, Feilim Mac Gabhann

Open access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sarvenaz SarabipourInstitute for Computational Medicine and Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, United States of America.ORCID 0000-0001-5097-5509
Karina KinghornCurriculum in Cell Biology and Physiology, University of North Carolina, Chapel Hill, North Carolina, United States of America.ORCID 0000-0002-2736-220X
Kaitlyn M QuigleyDepartment of Biology, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Anita Kovacs-KasaVascular Biology Center and Department of Medicine, Medical College of Georgia at Augusta University, Augusta, Georgia, United States of America.
Brian H AnnexVascular Biology Center and Department of Medicine, Medical College of Georgia at Augusta University, Augusta, Georgia, United States of America.
Victoria L BautchCurriculum in Cell Biology and Physiology, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Feilim Mac GabhannInstitute for Computational Medicine and Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, United States of America.ORCID 0000-0003-3481-7740
University of North Carolina at Chapel Hill · USAugusta University · USJohns Hopkins University · US

Funding

Systems Biology of Angiogenesis in Peripheral Arterial DiseaseR01HL101200 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI POPEL, ALEKSANDER S. · 2010 to 2022
$10.7M
New Roles for VEGFR1 in AngiogenesisR01GM129074 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI MAC GABHANN, FEILIM C · 2018 to 2021
$2.6M
NHLBI NIH HHS R01 HL101200NIGMS NIH HHS R01 GM129074
6 · The paper itself

Abstract

The vascular endothelial growth factor (VEGF) family of cytokines are key drivers of blood vessel growth and remodeling. These ligands act via multiple VEGF receptors (VEGFR) and co-receptors such as Neuropilin (NRP) expressed on endothelial cells. These membrane-associated receptors are not solely expressed on the cell surface, they move between the surface and intracellular locations, where they can function differently. The location of the receptor alters its ability to 'see' (access and bind to) its ligands, which regulates receptor activation; location also alters receptor exposure to subcellularly localized phosphatases, which regulates its deactivation. Thus, receptors in different subcellular locations initiate different signaling, both in terms of quantity and quality. Similarly, the local levels of co-expression of other receptors alters competition for ligands. Subcellular localization is controlled by intracellular trafficking processes, which thus control VEGFR activity; therefore, to understand VEGFR activity, we must understand receptor trafficking. Here, for the first time, we simultaneously quantify the trafficking of VEGFR1, VEGFR2, and NRP1 on the same cells-specifically human umbilical vein endothelial cells (HUVECs). We build a computational model describing the expression, interaction, and trafficking of these receptors, and use it to simulate cell culture experiments. We use new quantitative experimental data to parameterize the model, which then provides mechanistic insight into the trafficking and localization of this receptor network. We show that VEGFR2 and NRP1 trafficking is not the same on HUVECs as on non-human ECs; and we show that VEGFR1 trafficking is not the same as VEGFR2 trafficking, but rather is faster in both internalization and recycling. As a consequence, the VEGF receptors are not evenly distributed between the cell surface and intracellular locations, with a very low percentage of VEGFR1 being on the cell surface, and high levels of NRP1 on the cell surface. Our findings have implications both for the sensing of extracellular ligands and for the composition of signaling complexes at the cell surface versus inside the cell.

Indexed as

Vascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1HumansHuman Umbilical Vein Endothelial CellsNeuropilin-1PhosphorylationReceptors, Vascular Endothelial Growth FactorSignal TransductionVascular Endothelial Growth Factor Receptor-2Neuropilin-1Receptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2

Identifiers

PMID38324585
PMCPMC10878527
OpenAlexW4391594237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.